Does size matter? [4]

Nephrology Dialysis Transplantation

Volumn 22, Issue 9, 2007, Pages 2725-2726

  Heinze, Georg ^a   Oberbauer, Rainer ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

GRAFT SURVIVAL; HAZARD RATIO; HUMAN; KIDNEY TRANSPLANTATION; LETTER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; SURVIVAL TIME; PROTEINURIA; SURVIVAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; PROTEINURIA; SURVIVAL ANALYSIS;

EID: 34548443455     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm310     Document Type: Letter

References (2)

1. Opelz G, Zeier M, Laux G, Morath C, Dohler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: A collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257-3262
2. Heinze G, Mitterbauer C, Regele H et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889-899